UNSPSC 51141585: Vinpocetine

This classification denotes an anticonvulsant, antihypertensive agent, and calcium channel blocker with the molecular formula C22H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 543512OBTC, chemically known as 3-alpha,16-alpha-apovincaminic acid ethyl ester but generally known as vinpocetine, which bears US NIH Compound Identifier 5673. European Medicines Agency schedules Vinpocetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00070MIG.

UNSPSC 51141585 Vinpocetine, a Commodity code, shows little relevant recent activity. The three recent state and local opportunities tagged under this code—a naloxone and drug deactivation systems procurement from Seminole County, an RFI from Texas HHS on direct-to-manufacturer pharmacy programs, and a cooperative purchasing RFP from Minnesota MMCAP for generic multi-source pharmaceuticals and OTC products—do not align with vinpocetine procurement. Vinpocetine is a prescription pharmaceutical with a specific therapeutic indication, whereas the recent solicitations target either harm-reduction supplies, pharmacy benefit program architecture, or broad-based generic and OTC product distribution. The mismatch suggests either miscoding at the issuing-body level or minimal actual procurement activity in this Commodity category during the recent period.

The issuing bodies across these three records span state agencies (Texas HHS, Minnesota Department of Administration via MMCAP cooperative vehicle), county government (Seminole County), and multistate alliance membership. Geographic activity appears in Texas, Minnesota, Florida, and Oregon. Without additional recent opportunities properly classified to vinpocetine, the code does not present actionable market signals for vendors focused on this specific pharmaceutical product line.